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Several desmin mutations have been described in patients with 
cardiomyopathies and distal myopathies. Among them, A213V 
substitution has been associated with three completely different 
clinical phenotypes: restrictive cardiomyopathy, dilated cardio-
myopathy and isolated distal myopathy. However, the identifica-
tion of this substitution also in control subjects has highlighted 
the question if the A213V shift represents a conditional mutation, 
giving rise to cardiomyopathy only in the presence of other predis-
posing factors. The aim of the present work was to study the po-
tential role of this substitution in predisposing to heart dilation.
Methods and results. We screened 108 patients with heart dilation 
due to ischemic heart disease, alcoholic cardiomyopathy or viral 
myocarditis, and 300 healthy controls for the presence of A213V 
substitution by direct sequencing and confirmed the results by 
site-specific restriction. In the control group A213V substitution 
was identified in 3 out of 300 patients, representing a rare poly-
morphism with a frequency of approximately 1%, which cor-
responds to the earlier reported frequency. In the study group 
A213V substitution was found in 5 out of 108 cases, correspond-
ing to approximately 4.6% (p < 0.035). Therefore we conclude 
that A213V desmin substitution represents a conditional muta-
tion, i.e. a rare polymorphism that plays a role as a predisposing 
factor resulting in maladaptive heart remodelling in the presence 
of other pathological factors. 
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Introduction
Desmin is a chief intermediate filament of muscle 
cells. It is highly expressed postnatally in all types of 
muscle tissue where it contributes to the structural and 
mechanical integrity of the skeletal and cardiac myo-
cytes as well as smooth muscle cells (1). It connects 
to the sarcomere at the level of the Z-discs, and serves 
as a linker between neighboring myofibrils, thus, pro-
viding  their  simultaneous  and  effective  contraction. 
It is also involved in proper mitochondrial position-
ing,  ensuring  mitochondrial  membrane  stability  and 
proper mitochondrial function (2). Recently, besides 
just structural functions, desmin along with some other 
Z-disk associated proteins has been shown to play an 
important role in mechanosensing and mechanotrans-
duction (3, 4). 
Desmin mutations have been associated with cardiac 
disorders, such as cardiomyopathies (dilated, restrictive 
or hypertrophic), and with skeletal myopathy (5). More 
than 40 different desmin mutations have been described 
up to date with most of them giving rise to combined 
cardiac and skeletal muscle phenotype. In terms of the 
prevalence, desmin mutations have been shown to be a 
rare cause of dilated cardiomyopathy (1-2%), whereas it 
is found in a considerably larger proportion of restrictive 
cardiomyopathies  in  association  with  intracellular  ag-
gregates and conduction defects (6-9). Recently A213V 
desmin substitution has been described in seven unrelat-
ed patients with three different phenotypes; distal skel-
etal  myopathy,  restrictive  cardiomyopathy,  and  dilated 
cardiomyopathy (8, 10, 11). However, this substitution 
has been found also in control groups with a frequency 
of approximately 1%, and has also been described in a 
familial case of dilated cardiomyopathy where it did not 
segregate with the disease phenotype (6). Therefore, it 
was suggested that A213V substitution represents a rare 
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polymorphism rather than a true disease-causing muta-
tion. Our group has previously described this substitution 
in a patient with late onset and rapid progression of heart 
dilation, no signs of coronary artery disease or previous 
myocardial infarction, but with a long history of arterial 
hypertension (8). We therefore hypothesize that A213V 
substitution can play a predisposing role in heart dilation 
in presence of other provocative and unfavorable factors. 
This hypothesis of A213V constituting a conditional mu-
tation was here tested by comparing the frequency of the 
desmin A213V substitution in a group of patients with 
heart dilation due to various factors to the frequency in a 
healthy control group. 
Materials and methods
Patient cohort
The  study  group  included  patients  with  sings  of 
heart failure (NYHA class II-IV) and enlarged left ven-
tricle dimensions (LVEDD > 56 mm) with preserved of 
decreased contractile function due to various etiologies: 
ischemic heart disease, arterial hypertension, metabolic 
syndrome, alcoholic cardiomyopathy and inflammatory 
cardiomyopathy. They patients with genetic dilated car-
diomyopathy (familial or sporadic forms) were excluded 
from the study. Totally, 108 patients with heart failure 
and cardiac dilation were included in the study group. 
Of these 70 (65%) were due to ischemic heart disease, 
including 19 (17.5%) post MI, 14 (13%) with metabolic 
syndrome and arterial hypertension, 10 (9%) with alco-
holic cardiomyopathy and 14 (13,%) with inflammatory 
cardiomyopathy. Clinical data and case history were ob-
tained  by  direct  physical  examination  during  patient’s 
visit and from medical records. Echocardiography was 
performed  according  to  standard  protocol. Written  in-
formed consent was obtained prior to patient enrollment 
and was approved by the local ethical committees of Al-
mazov Federal Centre, St.Petersburg and Stockholm. The 
control group included 300 healthy donors with the same 
Caucasian background. 
Sequencing of the desmin gene
Genomic DNA was extracted from peripheral blood 
using a phenol-chlorophorm purification method. Exon 2 
of the desmin gene (DES) including exon-intron bounda-
ries was amplified by PCR followed 
by direct DNA sequencing (8). In all 
cases  A213V  substitution  has  been 
confirmed  by  restriction  enzyme 
analysis, since A213V substitution in-
troduces a restriction site for AccBsI, 
thus, cutting the original 384 bp PCR 
product to 103+281 fragments. 
Statistical analysis 
Echocardiography data were analyzed using a Stu-
dent’s t-test and expressed as mean ± SD. The difference 
in the distribution of genotypes between the study group 
and controls was statistically analyzed by means of the 
Fisher’s exact test to obtain a P value. A P value of less 
than 0.05 was considered significant. Odds ratios (OR) 
and 95% confidence intervals (95% CI) were calculated 
to express the strength of the association between a poly-
morphism and the disease.
Results
Direct sequencing of DES exon 2 revealed A213V sub-
stitution in 5 patients from the study group, and in 3 cases 
from control group (4.6% and 1% respectively, P < 0.035, 
Table  1).  There  was  no  significant  difference  in  mean 
echocardiography values between patients with and with-
out A213V substitution in the study group (Table 2). The 
major cause of heart failure in a patient 1 was ischemic 
heart disease without arterial hypertension or metabolic 
syndrome, complicated with ST-myocardial infarction 7 
years prior to examination. Patients 2 and 3 both had met-
abolic syndrome including arterial hypertension, dyslipi-
demia and diabetes mellitus. Patient 4 was a young man 
suffering from chronic post-viral myocarditis confirmed 
by  Dallas  criteria  after  endomyocardial  biopsy  4  yeas 
prior to examination. In patient 5 dilated cardiomyopathy 
was observed in combination with arterial hypertension 
and Marfan-like connective tissue disorder phenotype. 
Discussion
Desmin A213V substitution has previously been de-
scribed in different cardiac/muscle phenotypes. The first 
patient, described in Holland, had skeletal distal myopa-
thy and no cardiac phenotype (10). In spite of concomitant 
double-mutation in the alpha–glucosidase gene, skeletal 
muscle biopsy with desmin and αB crystalline -positive 
protein aggregates and with no evidence of glycogen or 
phosphatase-positive  vacuoles  strongly  suggested  the 
A213V desmin shift to be disease causing. The second 
A213V substitution was described in a familial case of 
restrictive cardiomyopathy without signs of skeletal mus-
cle affection, where A213V substitution segregated with 
Table 1. Direct sequencing of DES exon 2.
Genotype Study group (n = 108) Control group (n = 300)
A213A 105 (95.5%) 297 (99%)
A213V 5 (4.6%) 3 (1%)
P < 0.035 CI – 1.1-20.0 OR 4.7A. Kostareva et al.
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the disease (11). Further, our group previously described 
this substitution in a patient with late-onset dilated cardi-
omyopathy, first degree AV block and left bundle branch 
block. However, findings from Taylor et al. put a directly 
causative role of the A213V substitution at question. The 
substitution was found in one large pedigree with famil-
ial DCMP out of 116 families studied, as well as in 6 
out of 306 non-familial cases (6). While absence of clini-
cal symptoms in several A213V carriers from this study 
could be explained by low penetrance, absence of this 
substitution in one affected family member almost ulti-
mately excludes its exclusive primary disease-causing na-
ture. However the possibility that A213V is a rare allelic 
variant, predisposing to malign cardiac remodeling as a 
conditional mutation has not previously been analyzed. 
In our study the frequency of A213V substitution in 
control group correspond to the earlier reports and consti-
tutes approximately 1% (6-8). However, overrepresenta-
tion of A213V in the group with cardiac dilation strongly 
supports that this substitution may have an unfavorable 
impact on cardiac remodeling under various stress condi-
tions. If so, it is particular interesting to unravel a mecha-
nism, by which structural polymorphism of desmin in-
fluences a pattern of cardiac remodeling. In our study 
we did not see any overt gross alterations of desmin or 
vimentin filament network in A213V desmin transfected 
HeLa cells. A213V desmin is able to participate in fine 
filamentous network and does not appear, at the light mi-
croscope level, to interfere with vimentin filaments. This 
corresponds to the earlier data from our as well as other 
groups, obtained on different cell types (6, 10). However, 
it does cause aberrant IF assembly as monitored by vis-
cometer analysis, a very sensitive tool to assess filament 
aggregation (12). Further, it has been found that patholog-
ical effect of mutant desmin does not completely correlate 
with the ability of aggregate formation (12, 13). Kreplack 
et. al showed severe alteration of nanomechanical prop-
erties of two C-terminal desmin rod domain mutations 
in spite of their ability to form filamentous network and 
absence of desmin aggregates in transfected cells (14). If 
this is true also for A213V substitution, altered biophysi-
cal properties of A213V desmin can predispose to cardiac 
vulnerability under certain stress conditions. 
Recently,  Z-disks  were  shown  to  be  an  important 
element of mechanical stretch sensing machine. Several 
desmin and Z-disk associated proteins as well as desmin 
itself have been shown to play an important role in de-
velopment  of  cardiac  hypertrophy  induced  by  various 
stimuli (15-18). In this context, modified properties of 
A213V desmin can predispose to altered adaptation of 
muscle cells to external and internal stress factors, such 
as pressure overload, ischemia or impaired metabolism. 
This could be a case, for example, in a patient with al-
pha-glucosidase gene deficiency in skeletal muscles, in 
patients with impaired glucose metabolism or in patient 
with connective tissue disorders. This substitution is like-
ly to be of less importance in familial cases of DCMP, 
where genetic origin of the disorder due to severe altera-
tions in myocyte proteins by itself is sufficient to cause a 
clinical phenotype. However, in non-genetic DCMP and 
in patients with heart dilation due to other acquired caus-
es where many other factors besides genetic play a pivotal 
role this substitution can make sense as a conditional mu-
tuation. It is interesting to note that another rare polymor-
phism of cardiomyocyte structural protein nebulette has 
been shown to associate with non-familial DCMP, but not 
with familial cases (19). Therefore it could be particular 
important to study rare gene variants and their impact on 
cardiac remodeling, since genome-wide approach, gen-
erally accepted now for searching new disease-causing 
and disease-modifying genes, usually does not cover rare 
polymorphisms with a frequency 5% and less. 
In conclusion, we have shown that the A213V substi-
tution represents a rare polymorphism with a population 
frequency of approximately 1%, that is overrepresented 
in patients with heart dilation of various origins (4,6%). 
This makes it most likely that the A213V shift constitutes 
a conditional mutation predisposing to malign cardiac re-
Table 2. Mean echocardiography values observed in patients with and without A213V substitution.
LVEDD LVESD RVEDD LA LVPWd LVPWs IVSd IVSs EF
Pat.1 61 49 37 57.8 12.3 18.2 12.6 15 31.42
Pat.2 63 49 37.3 48 16 17 14 16 44.5
Pat.3 56 29.4 23.1 53.9 10.5 16.4 12.6 15.5 55.7
Pat.4 74 59 34 45 12.3 12.3 9.5 9.9 27.9
Pat.5 62 42.6 22.4 48 8.2 17.1 9.7 13.5 28
Mean
A213V group
63.2
± 5.9
45
± 10.8
29.2
± 7.4
48.7
± 5.1
11.8
± 2.8
15.7
± 2.2
11.5
± 1.9
13.7
± 2.4
39
± 12.2
Mean
study group
62.2
± 6.6
49.2
± 11.9
29.5
± 6.9
50.5
± 8.1
10.0
± 2.0
14.1
± 3.2
10,7
± 2.9
12.8
± 3.1
37.7
± 14.9Desmin A213V substitution represents a rare polymorphism but not a mutation
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modeling under other stressful conditions. More studies 
A213V desmin biomechanical properties can shed light 
on the detailed mechanisms, involved in cardiac malad-
aptation in A213V patients. 
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